The perverse incentives is also a very real issue.
Who is going to pay? Early stage drugs are still figuring out their manufacturing process, and quantities can be extremely limited. Say you give drug X to a sick patient and they die, what then? Was it because of the novel drug? Not a favorable position to have more deaths associated with your treatment. Can you draw any data from these patients to inform further trials? Also complicated because end stage patients have already exhausted other options and the interaction with other compounds can make disentangling this harder.
In particular drugs should still be checked for efficacy before getting on that list.
But requirements for long term safety and side effects when people die in a year should be relaxed.
What am I missing? For non-terminal diseases, it's a bit murkier, but still I don't follow the analogy.
I do think we’re overly cautious with drug approvals and I think we should be more open to leaving the decision to patients and their medical teams, but it’s not as simple as saying someone’s terminally ill, so just do whatever. Reducing it down to the trolley problem makes it seem much more black and white and immediate than it really is.
Access to experimental treatments also opens up more perverse incentives where desperate people are likely to try anything.